Marks Group Wealth Management Inc Buys 504 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Marks Group Wealth Management Inc raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,857 shares of the medical research company’s stock after acquiring an additional 504 shares during the period. Marks Group Wealth Management Inc’s holdings in Thermo Fisher Scientific were worth $4,701,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in Thermo Fisher Scientific by 0.6% in the third quarter. Vanguard Group Inc. now owns 32,760,738 shares of the medical research company’s stock worth $16,582,503,000 after buying an additional 180,618 shares during the last quarter. Morgan Stanley lifted its position in Thermo Fisher Scientific by 0.4% in the 3rd quarter. Morgan Stanley now owns 12,418,429 shares of the medical research company’s stock valued at $6,285,838,000 after acquiring an additional 50,736 shares in the last quarter. Northern Trust Corp boosted its stake in Thermo Fisher Scientific by 2.6% during the 3rd quarter. Northern Trust Corp now owns 3,929,225 shares of the medical research company’s stock valued at $1,988,856,000 after purchasing an additional 99,377 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Thermo Fisher Scientific by 9.8% in the third quarter. Wellington Management Group LLP now owns 3,080,687 shares of the medical research company’s stock worth $1,559,351,000 after purchasing an additional 274,464 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Thermo Fisher Scientific by 0.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,184,928 shares of the medical research company’s stock valued at $1,105,945,000 after purchasing an additional 8,672 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Activity

In other news, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the sale, the senior vice president now owns 12,901 shares in the company, valued at $7,250,362. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the sale, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the completion of the sale, the chief executive officer now owns 49,155 shares in the company, valued at approximately $27,311,992.65. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 50,277 shares of company stock worth $28,513,384. Corporate insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Trading Up 4.9 %

TMO stock opened at $575.10 on Wednesday. The firm has a fifty day moving average price of $572.03 and a 200 day moving average price of $528.72. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.39 and a current ratio of 1.75. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $603.82. The firm has a market cap of $219.52 billion, a PE ratio of 37.22, a price-to-earnings-growth ratio of 2.31 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The firm had revenue of $10.89 billion during the quarter, compared to analysts’ expectations of $10.73 billion. During the same quarter in the previous year, the business earned $5.40 EPS. The company’s quarterly revenue was down 4.9% on a year-over-year basis. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.51 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were issued a dividend of $0.39 per share. The ex-dividend date was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio is currently 10.10%.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of recent analyst reports. Evercore ISI boosted their target price on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. Raymond James boosted their target price on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. Sanford C. Bernstein reissued a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Royal Bank of Canada upped their target price on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. Finally, HSBC upped their price target on Thermo Fisher Scientific from $630.00 to $660.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. Five investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $604.69.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.